Gujarat Exclusive > National-World > Man files complaint against Adar Poonawalla, claims “no antibodies developed after taking Covishield

Man files complaint against Adar Poonawalla, claims “no antibodies developed after taking Covishield


A Lucknow resident, Pratap Chandra, has filed a complaint against Pune-based Serum Institute of India’s (SII) CEO Adar Poonawalla, health ministry’s joint secretary Luv Agarwal, Indian Council of Medical Research director Balram Bhargava, and National Health Mission director Aparna Upadhyay, claiming that he did not develop any antibody against COVID-19 after taking a Covishield jab.

Chandra, in his complaint, said that he received the first dose of the vaccine on April 8 and was not feeling well after receiving the jab. He could not take the second dose of the jab after 28 days as the Centre extended the gap between the two doses to 6 weeks. Thereafter, it was extended to 12 weeks.

Citing ICMR director general Balram Bhargava’s quotes in media where he had said “good levels of antibodies are produced in the body after the first dose of Covishield”, the complainant took a COVID Antibody GT test from a government-approved lab.

The test result revealed that the complainant did not develop any antibodies against COVID-19. Instead, his platelets were reduced to 1.5 lakh from 3 lakh. Chandra alleged that after taking the vaccine he has become more prone to the virus as his platelet count has been reduced by half.

FIR not registered against Adar Poonawalla

Although the police have registered the complaint, an FIR has not been registered. Due to the sensitivity of the matter, the cops have informed senior officials regarding the complaint before a decision is taken.

Pratap Chandra, however, has threatened to move court if the police refuse to register an FIR against the people named in the complaint.

Vaccines approved in India

The Indian drug regulator has so far approved three COVID-19 vaccines for emergency use in India. It includes Covishield developed by AstraZeneca and the University of Oxford and locally manufactured in India by Serum Institute, Bharat Biotech’s Covaxin, and Russia’s Sputnik V.


To read the latest news in Gujarati click here